Volume 83, Issue 5

Search all Cancer Chemotherapy and Pharmacology articles

May 2019

21 articles in this issue

Regorafenib regressed a doxorubicin-resistant Ewing’s sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model
Kentaro Miyake
Tasuku Kiyuna
Robert M. Hoffman
Original Article 13 February 2019 Pages: 809 - 815
Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation
Ou Yamaguchi
Kyoichi Kaira
Hiroshi Kagamu
Original Article 13 February 2019 Pages: 817 - 825
Potential drug–drug interactions and nephrotoxicity in hematopoietic stem cell transplant adult recipients during bone marrow transplantation unit stay
Lydia Sanchez
Astrid Bacle
Pascal Le Corre
Original Article 13 February 2019 Pages: 827 - 835
Pharmacokinetics, absorption, metabolism, and excretion of [¹⁴C]ivosidenib (AG-120) in healthy male subjects
Chandra Prakash
Bin Fan
Hua Yang
Original Article 13 February 2019 Pages: 837 - 848
Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer
Toshio Kawata
Mitsuo Higashimori
Yusuke Tanigawara
Original Article Open access 14 February 2019 Pages: 849 - 858
SCMCIE94: an intensified pilot treatment protocol known to be associated with cure in CD 56-negative non-pelvic isolated Ewing sarcoma (EWS) is also associated with no early relapses in non-metastatic extremity EWS
Ian Joseph Cohen
Helen Toledano
Shifra Ash
Original Article 15 February 2019 Pages: 859 - 866
A study of second-line irinotecan plus cisplatin vs. irinotecan alone in platinum-naïve patients with early relapse of gastric cancer refractory to adjuvant S-1 monotherapy: exploratory subgroup analysis of the randomized phase III TRICS trial
Kazuhiro Nishikawa
Kenta Murotani
Toshimasa Tsujinaka
Original Article 26 February 2019 Pages: 867 - 874
Classification and regression tree-based prediction of 6-mercaptopurine-induced leucopenia grades in children with acute lymphoblastic leukemia
Shaik Mohammad Naushad
Patchava Dorababu
Vijay Kumar Kutala
Original Article 26 February 2019 Pages: 875 - 880
Safety assessment of anticancer drugs in association with radiotherapy in metastatic malignant melanoma: a real-life report
Emmanuelle Couty
Alexis Vallard
Nicolas Magné
Original Article 26 February 2019 Pages: 881 - 892
Irinotecan induces enterocyte cell death and changes to muc2 and muc4 composition during mucositis in a tumour-bearing DA rat model
Daniel Thorpe
Masooma Sultani
Andrea Stringer
Original Article 27 February 2019 Pages: 893 - 904
Determination of melphalan in human plasma by UPLC–UV method
Liusheng Huang
Vincent Cheah
Janel Long-Boyle
Original Article 13 February 2019 Pages: 905 - 910
Disruption of CTLA-4 expression on peripheral blood CD8 + T cell enhances anti-tumor efficacy in bladder cancer
Wei Zhang
Long Shi
Jianhui Cai
Original Article 08 March 2019 Pages: 911 - 920
The PVT1/miR-216b/Beclin-1 regulates cisplatin sensitivity of NSCLC cells via modulating autophagy and apoptosis
Liangfeng Chen
Xiaobing Han
Liangxin Chen
Original Article 11 March 2019 Pages: 921 - 931
The impact of genetic polymorphism on CYP19A1 in androgen-deprivation therapy among Japanese men
Masaki Shiota
Naohiro Fujimoto
Masatoshi Eto
Original Article 13 March 2019 Pages: 933 - 938
CDA and MTHFR polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine-based chemotherapy
Duo Liu
Xiang Li
Mei Dong
Original Article 15 March 2019 Pages: 939 - 949
A novel method to address the association between received dose intensity and survival outcome: benefits of approaching treatment intensification at a more individualised level in a trial of the European Osteosarcoma Intergroup
Carlo Lancia
Jakob K. Anninga
Marta Fiocco
Original Article Open access 16 March 2019 Pages: 951 - 962
Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours
Peng Yuan
Jianzhong Shentu
Binghe Xu
Original Article 18 March 2019 Pages: 963 - 974
TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer
Davide Melisi
Rocio Garcia-Carbonero
Josep Tabernero
Original Article 18 March 2019 Pages: 975 - 991
Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38
Mariko Iwase
Ken-ichi Fujita
Yuji Kiuchi
Short Communication 13 February 2019 Pages: 993 - 998
Eligibility criteria for phase I clinical trials: tight vs loose?
Laeeq Malik
David Lu
Short Communication 27 February 2019 Pages: 999 - 1002
The clinical added value of the addition of anti-CTL-4 to anti-PD-1 alone is questionable and clearly increasing toxicity regarding pivotal studies in the treatment of melanoma and renal carcinoma
Nicolas Albin
Adrien Monard
Jérémy Lapiere
Letter to the Editor 04 March 2019 Pages: 1003 - 1005

Volume 83, Issue 5

Regorafenib regressed a doxorubicin-resistant Ewing’s sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model

Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation

Potential drug–drug interactions and nephrotoxicity in hematopoietic stem cell transplant adult recipients during bone marrow transplantation unit stay

Pharmacokinetics, absorption, metabolism, and excretion of [¹⁴C]ivosidenib (AG-120) in healthy male subjects

Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer

SCMCIE94: an intensified pilot treatment protocol known to be associated with cure in CD 56-negative non-pelvic isolated Ewing sarcoma (EWS) is also associated with no early relapses in non-metastatic extremity EWS

A study of second-line irinotecan plus cisplatin vs. irinotecan alone in platinum-naïve patients with early relapse of gastric cancer refractory to adjuvant S-1 monotherapy: exploratory subgroup analysis of the randomized phase III TRICS trial

Classification and regression tree-based prediction of 6-mercaptopurine-induced leucopenia grades in children with acute lymphoblastic leukemia

Safety assessment of anticancer drugs in association with radiotherapy in metastatic malignant melanoma: a real-life report

Irinotecan induces enterocyte cell death and changes to muc2 and muc4 composition during mucositis in a tumour-bearing DA rat model

Determination of melphalan in human plasma by UPLC–UV method

Disruption of CTLA-4 expression on peripheral blood CD8 + T cell enhances anti-tumor efficacy in bladder cancer

The PVT1/miR-216b/Beclin-1 regulates cisplatin sensitivity of NSCLC cells via modulating autophagy and apoptosis

The impact of genetic polymorphism on CYP19A1 in androgen-deprivation therapy among Japanese men

CDA and MTHFR polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine-based chemotherapy

A novel method to address the association between received dose intensity and survival outcome: benefits of approaching treatment intensification at a more individualised level in a trial of the European Osteosarcoma Intergroup

Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours

TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer

Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38

Eligibility criteria for phase I clinical trials: tight vs loose?

The clinical added value of the addition of anti-CTL-4 to anti-PD-1 alone is questionable and clearly increasing toxicity regarding pivotal studies in the treatment of melanoma and renal carcinoma

Navigation